In a rare mis­fire, Re­gen­eron scraps its RSV drug af­ter a PhI­II fail­ure

In a rare Phase III fail­ure, Re­gen­eron says its late-stage an­ti­body for RSV — sup­tavum­ab (REGN2222) — flopped in a ma­jor study which en­rolled more than a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.